Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the vaginal and vulval inflammatory disease treatment market grown in recent years?
The market for treating vaginal and vulval inflammatory diseases has significantly expanded in the past few years. The market size is predicted to swell from $2.87 billion in 2024 to $3.06 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.65%. The surge during the historic period is a result of increasing instances of vaginal infections, heightened consciousness regarding women’s health, enhancement in healthcare structures, a growing senior population, and escalating urbanization.
How is the vaginal and vulval inflammatory disease treatment market size expected to evolve during the forecast period?
In the coming years, the market for vaginal and vulval inflammatory disease treatment is projected to experience robust growth, reaching a value of $3.92 billion by 2029 with a compound annual growth rate (CAGR) of 6.39%. This projected growth during the forecast period can be tied to a surge in vulvovaginal health awareness, an increased demand for non-invasive treatment methods, a rise in chronic inflammatory diseases, better access to healthcare, and an increased number of medical professionals. The forecast period is also likely to witness major trends like advancements in diagnostic tool technology, the use of artificial intelligence in diagnostics, home-care solutions, the creation of vaginal vaccines, and the introduction of minimally invasive surgical procedures.
Get your vaginal and vulval inflammatory disease treatment market report here!
Which key drivers are propelling the vaginal and vulval inflammatory disease treatment market’s growth?
The rise in diabetes cases is anticipated to fuel the expansion of the market for treatment of vaginal and vulval inflammatory diseases. Diabetes, a long-term health condition characterized by high blood sugar levels, arises due to the body’s inability to either manufacture or adequately utilize insulin. Sedentary lifestyle, poor diet habits, increasing obesity, genetic susceptibility, and an aging global population are all contributing factors to the rising prevalence of diabetes. Vaginal and vulval inflammatory disease treatment can assist diabetes patients by reducing the frequency of infections, common with high blood sugar levels and a compromised immune system, while also enhancing insulin receptivity and overall glucose control. For instance, data from the UK’s Office for Health Improvement & Disparities shows that between March 2022 and March 2023, the percentage of people with type 1 diabetes receiving all eight recommended care processes rose by 22%. Concurrently, for those with type 2 diabetes, there was a 21% increase and the percentage reaching target HbA1c levels reached 37.9%, representing the highest figure ever documented by the National Diabetes Audit (NDA). Therefore, the escalating diabetes rates are spurring the progression of the market for treatment of vaginal and vulval inflammatory diseases.
What are the market segments in the vaginal and vulval inflammatory disease treatment industry?
The vaginal and vulval inflammatory disease treatment market covered in this report is segmented –
1) By Indication: Vaginal Dryness, Vaginal Burning, Vaginal Discharge, Genital Itching, Recurrent Urinary Tract Infections, Urinary Incontinence, Other Indications
2) By Treatment: Anti-Itch Medications, Corticosteroid Ointments, Anti-Itch Emollients
3) By End User: Hospital Pharmacies, Specialty Clinics, Other End-Users
Subsegments:
1) By Vaginal Dryness: Hormonal Therapy, Non-Hormonal Moisturizers, Lubricants and Topical Agents
2) By Vaginal Burning: Anti-inflammatory Creams and Gels, Topical Steroids, Pain Relief Medications
3) By Vaginal Discharge: Antifungal Treatments, Antibacterial Treatments, Probiotics and Prebiotics
4) By Genital Itching: Antihistamines, Topical Corticosteroids, Antifungal Treatments
5) By Recurrent Urinary Tract Infections (UTIs): Antibiotics, Probiotics, Cranberry-based Supplements
6) By Urinary Incontinence: Behavioral Therapy, Medications (Anticholinergics, Beta-3 Agonists), Surgical Interventions
7) By Other Indications: Lichen Sclerosus, Vaginal Atrophy, Pelvic Floor Dysfunction, Vulvar Vestibulitis
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20994&type=smp
Which leading companies are shaping the growth of the vaginal and vulval inflammatory disease treatment market?
Major companies operating in the vaginal and vulval inflammatory disease treatment market are Pfizer Incorporated, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Hologic Inc., Ferring Pharmaceuticals, Venus Concept Inc., Kyung Hee University Medical Center, Duchesnay Inc., Evofem Biosciences Inc., SEID Lab, Curive Healthcare Inc., Replens, MC2 Therapeutics ApS, FemiClear
What emerging trends are influencing the growth of the vaginal and vulval inflammatory disease treatment market?
Major companies operating in the vaginal and vulval inflammatory disease treatment market are focusing on developing innovative products such as vaginal synbiotics to enhance treatment efficacy and improve patient outcomes. A vaginal synbiotic refers to a combination of probiotics and prebiotics specifically formulated to support the health of the vaginal microbiome, promoting balance and preventing infections. For instance, in May 2024, Seed Health Inc., a US-based biotechnology company, introduces VS-01, a groundbreaking vaginal microbiome innovation designed to revolutionize vaginal care. This first-of-its-kind product focuses on promoting vaginal health through a scientifically backed formulation designed to support the microbiome balance. VS-01 features a proprietary blend of probiotics that target the delicate ecosystem of the vaginal microbiome, helping to maintain its natural defenses. By leveraging advanced microbiome science, the product addresses issues like imbalances and discomfort, offering a holistic solution for women seeking to enhance their vaginal health.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20994
Which geographic areas are influencing the growth of the vaginal and vulval inflammatory disease treatment market?
North America was the largest region in the vaginal and vulval inflammatory disease treatment market in 2024. The regions covered in the vaginal and vulval inflammatory disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Bronchodilators Global Market Report 2025
https://thebusinessresearchcompany.com/report/bronchodilators-global-market-report
Vaginal Sling Global Market Report 2025
https://thebusinessresearchcompany.com/report/vaginal-sling-global-market-report
Vaginitis Therapeutics Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/vaginitis-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
